Status:
COMPLETED
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Glioblastoma
Glioma
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation. The investigators hope to learn wheth...
Eligibility Criteria
Inclusion
- Histologically confirmed glioblastoma multiforme
- Ages 18-65
- Karnofsky Performance Scale (KPS) equal to or less than 70
- Minimal neurological deficit
- Eligible for concurrent temozolomide chemotherapy
Exclusion
- Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00250211
Start Date
March 1 2005
End Date
April 1 2011
Last Update
February 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2